Austin Murtagh | Stern Investor Relations |
Gregory Divis | Chief Executive Officer |
Richard Kim | Chief Commercial Officer |
Jennifer Gudeman | Senior Vice President, Medical and Clinical Affairs |
Thomas McHugh | Chief Financial Officer |
Francois Brisebois | Oppenheimer |
Andrew Tsai | Jefferies |
Ami Fadia | Needham & Company |
Marc Goodman | Leerink |
Matthew Kaplan | Ladenburg Thalmann |
Chase Knickerbocker | Craig Hallum |
Myriam Belghiti | LifeSci Capital |
Greetings, and welcome to Avadel Pharmaceuticals Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.
As a reminder, this conference is being recorded.
It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations.